Expression levels of gasdermin family members and systemic inflammatory cytokines differ significantly across histological subtypes of ovarian cancer, according to a comparative investigation published in Medical Oncology. Tissue and serum analyses revealed marked subtype-dependent variations in these pyroptosis-related markers at both the mRNA and protein levels. Most notably, researchers observed that protein concentrations of both GSDMB and GSDMF were significantly reduced in high-grade serous ovarian tumors compared with benign, histologically normal ovarian tissues collected from healthy control women. In addition, GSDMB protein levels were found to be decreased in endometrioid ovarian tumors compared to normal ovarian tissue specimens.
The research addresses a critical gap regarding how programmed cell death mechanisms operate in diverse ovarian tumor environments. Gasdermin family members serve as key effector proteins that execute pyroptosis, a specialized pro-inflammatory form of programmed cell death. This cellular process is characterized by the formation of pores in the plasma membrane and the subsequent release of pro-inflammatory cytokines into the surrounding microenvironment. Despite the recognized role of gasdermins in mediating inflammation, the specific relationship between gasdermin expression and systemic inflammatory responses across different histological subtypes of ovarian cancer had remained poorly understood prior to this study.
To systematically characterize these patterns, the research team quantified the mRNA and protein expression levels of six individual gasdermin family members across ovarian cancer specimens representing distinct histological subtypes. The analyzed malignant tissues included serous, endometrioid, clear cell, and mucinous ovarian tumors. To establish baseline comparisons, the investigators evaluated benign, non-malignant ovarian tissues that were confirmed to be histologically normal and obtained from healthy women without ovarian cancer. This experimental design enabled direct comparisons between healthy ovarian tissues and multiple distinct cancer subtypes.
In addition to evaluating primary ovarian tissue specimens, the study investigated whether gasdermin alterations could be tracked systemically. The investigators analyzed gasdermin expression profiles in peripheral blood samples collected from patients with ovarian cancer as well as from healthy control women. Furthermore, the team measured circulating concentrations of specific inflammatory cytokines in patient serum. These serum evaluations focused on interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), comparing individuals diagnosed with different histological subtypes of ovarian tumors against one another and against healthy control subjects.
The comparative measurements revealed important distinctions between localized tissue alterations and systemic circulating markers. Subtype-specific alterations in gasdermin mRNA expression were found to be substantially more prominent within ovarian tumor tissues than in the peripheral blood mRNA samples. Meanwhile, the serum cytokine evaluations demonstrated that patients diagnosed with serous and mucinous ovarian cancer had higher circulating levels of IL-1β and IL-18 compared to patients diagnosed with other histological subtypes of the disease. These findings show that cytokine elevation is not uniform across all presentations of ovarian cancer.
Overall, the study authors report that inflammatory responses vary among histological subtypes, pointing to the existence of distinct, subtype-specific inflammatory profiles within this highly heterogeneous malignant disease. The observed evidence suggests that gasdermin-mediated pyroptosis and its associated inflammatory pathways function differently depending on the specific histological subtype of ovarian cancer involved. Consequently, these differential pyroptotic mechanisms and inflammatory pathways may contribute directly to the widespread biological heterogeneity observed in ovarian cancer.
Subject of Research: Gasdermin expression and inflammatory profiles across ovarian cancer histological subtypes
Article Title: Histological subtype-specific gasdermin expression suggests distinct pyroptotic and inflammatory profiles in ovarian cancer
Article References: Keskin, A., Berkel, C., Yeldir, N., Akcay, E., Coskun, G., Evcil, E., Senol, R., Guler, A. H., Yurtcu, N., Ozdemir, I. A., Ozturk, Z., Ozer, H., & Cacan, E. (2026). Histological subtype-specific gasdermin expression suggests distinct pyroptotic and inflammatory profiles in ovarian cancer. Medical Oncology, 43(12), Article 392. https://doi.org/10.1007/s12032-026-03510-4
Image Credits: AI Generated
DOI: 10.1007/s12032-026-03510-4
Keywords: ovarian cancer, gasdermin family, pyroptosis, serous ovarian cancer, endometrioid ovarian cancer, mucinous ovarian cancer, clear cell ovarian cancer, high-grade serous tumors, GSDMB, GSDMF, interleukin-1 beta, interleukin-18, inflammatory cytokines, programmed cell death, plasma membrane pores, peripheral blood mRNA, histological subtypes, disease heterogeneity
Cite Scienmag News
Nathaniel Bowman. (November 18, 2026). Gasdermin Protein Levels Decrease in High-Grade Serous and Endometrioid Ovarian Cancers. Scienmag. https://scienmag.com/gasdermin-protein-levels-decrease-in-high-grade-serous-and-endometrioid-ovarian-cancers/
Nathaniel Bowman. "Gasdermin Protein Levels Decrease in High-Grade Serous and Endometrioid Ovarian Cancers." Scienmag, 18 November 2026, https://scienmag.com/gasdermin-protein-levels-decrease-in-high-grade-serous-and-endometrioid-ovarian-cancers/. Accessed 18 November 2026.
Nathaniel Bowman. "Gasdermin Protein Levels Decrease in High-Grade Serous and Endometrioid Ovarian Cancers." Scienmag. November 18, 2026. https://scienmag.com/gasdermin-protein-levels-decrease-in-high-grade-serous-and-endometrioid-ovarian-cancers/








